Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros

Bases de datos
País/Región como asunto
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Acta Neurol Taiwan ; 32(4): 207-211, 2023 Dec 30.
Artículo en Inglés | MEDLINE | ID: mdl-37723913

RESUMEN

PURPOSE: Guillain-Barré Syndrome (GBS) associated with SARS-CoV-2 vaccine administration is very rare. Early recognition of GBS at early stage could prevent extensive nerve damage with potential respiratory and autonomic failure. CASE REPORT: We report a case of paraparetic spectrum of GBS in a 53-year-old lady who presented with rapidly progressive acute flaccid paralysis involving both lower extremities with areflexia eight days after the first dose of Sinovac vaccine for SARS-CoV-2 in Malaysia. Cerebrospinal fluid (CSF) albuminocytological dissociation was seen and nerve conduction study (NCS) revealed sensory neuropathy. The diagnosis of GBS was made based on the Brighton criteria. Patient responded well to intravenous immunoglobulin (IVIG). CONCLUSION: Though there is currently no convincing evidence of any causation between GBS and SARS- CoV-2 vaccination, clinicians should remain vigilant and consider GBS in the differential diagnosis for patient who presents with weakness with reduced or absent deep tendon reflex after vaccination against SARS-CoV-2.


Asunto(s)
COVID-19 , Síndrome de Guillain-Barré , Femenino , Humanos , Persona de Mediana Edad , Síndrome de Guillain-Barré/diagnóstico , Síndrome de Guillain-Barré/etiología , Vacunas contra la COVID-19/efectos adversos , Malasia , SARS-CoV-2 , COVID-19/complicaciones , COVID-19/prevención & control , Vacunación
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA